The Clinical Pharmacokinetics of Itraconazole: An Overview
暂无分享,去创建一个
R. Woestenborghs | J. Heykants | V. Velde | J. Cutsem | G. Cauwenbergh | W. Meuldermans | K. Lavrijsen | P. Rooy | A. Peer
[1] S. Clissold,et al. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. , 1990, Drugs.
[2] J. Heykants,et al. Induction potential of fluconazole toward drug-metabolizing enzymes in rats , 1990, Antimicrobial Agents and Chemotherapy.
[3] P. Collignon,et al. INTERACTION OF FLUCONAZOLE WITH CYCLOSPORIN , 1989, The Lancet.
[4] A. S. Mitchell,et al. Fluconazole and phenytoin: a predictable interaction. , 1989, BMJ.
[5] G. Faggian,et al. Experience with itraconazole in cryptococcosis and aspergillosis. , 1989, The Journal of infection.
[6] C. Niemegeers,et al. Interference of antimycotics and other drugs with methohexital hypnosis in rats , 1989 .
[7] T. Blaschke,et al. Fluconazole is a potent inhibitor of antipyrine metabolism in vivo in mice. , 1989, Drug Metabolism And Disposition.
[8] S. Clissold,et al. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. , 1989, Drugs.
[9] M. Schurgers,et al. Itraconazole pharmacokinetics in patients with renal dysfunction , 1988, Antimicrobial Agents and Chemotherapy.
[10] E. Straus,et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.
[11] R. Hay,et al. An evaluation of itraconazole in the management of onychomycosis , 1988, The British journal of dermatology.
[12] J. Graybill,et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers , 1988, Antimicrobial Agents and Chemotherapy.
[13] B. Isalska,et al. Fluconazole in the treatment of candidal prosthetic valve endocarditis. , 1988, BMJ.
[14] H. Degreef,et al. Pharmacokinetic profile of orally administered itraconazole in human skin. , 1988, Journal of the American Academy of Dermatology.
[15] M. Gumbleton,et al. In-vivo effects of itraconazole on hepatic mixed-function oxidase. , 1988, The Journal of antimicrobial chemotherapy.
[16] J. Heykants,et al. Determination of cisapride in plasma and animal tissues by high-performance liquid chromatography. , 1988, Journal of chromatography.
[17] D. Warnock,et al. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. , 1988, The Journal of antimicrobial chemotherapy.
[18] D. Trenk,et al. TIME COURSE OF CYCLOSPORIN/ITRACONAZOLE INTERACTION , 1987, The Lancet.
[19] I. Nováková,et al. ITRACONAZOLE AND CYCLOSPORIN NEPHROTOXICITY , 1987, The Lancet.
[20] M. Gumbleton,et al. INTERACTION OF CYCLOSPORIN AND ITRACONAZOLE , 1987, The Lancet.
[21] R. Fromtling,et al. Recent Trends in the Discovery, Development, and Evaluation of Antifungal Agents , 1987 .
[22] J. Levron,et al. The pharmacokinetics of itraconazole in animals and man: an overview , 1987 .
[23] V. Schuermans,et al. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. , 1987, Reviews of infectious diseases.
[24] B. Dupont,et al. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. , 1987, Reviews of infectious diseases.
[25] W. Meuldermans,et al. Interaction of miconazole, ketoconazole and itraconazole with rat-liver microsomes. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.
[26] G. Tricot,et al. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. , 1987, Reviews of infectious diseases.
[27] R. Woestenborghs,et al. Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole. , 1986, European journal of obstetrics, gynecology, and reproductive biology.
[28] W. Meuldermans,et al. Induction potential of antifungals containing an imidazole or triazole moiety. Miconazole and ketoconazole, but not itraconazole are able to induce hepatic drug metabolizing enzymes of male rats at high doses. , 1986, Biochemical pharmacology.
[29] M J Humphrey,et al. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans , 1985, Antimicrobial Agents and Chemotherapy.
[30] J. Perfect,et al. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. , 1985, The Journal of antimicrobial chemotherapy.
[31] P. Marichal,et al. Molecular basis for the antimycotic and antibacterial activity of N‐substituted imidazoles and triazoles: The inhibition of isoprenoid biosynthesis , 1984 .
[32] H. Jones,et al. Orally administered ketoconazole: route of delivery to the human stratum corneum , 1983, Antimicrobial Agents and Chemotherapy.
[33] G. Acocella,et al. Interaction of rifampicin with other drugs. , 1980, Tubercle.
[34] V. Shah,et al. Griseofulvin levels in stratum corneum. Study after oral administration in man. , 1972, Archives of dermatology.
[35] V. Shah,et al. Determination of griseofulvin in skin, plasma, and sweat. , 1972, Journal of pharmaceutical sciences.